Use of PCA3 in detecting prostate cancer in initial and repeat prostate biopsy patients
Use of PCA3 in detecting prostate cancer in initial and repeat prostate biopsy patients
复制标题
DOI：
10.1002/pros.22538
复制
发表时间：
2013-01-01
期刊：
影响因子：
2.8
通讯作者：
Chevli, K. Kent
中科院分区：
文献类型：
--
作者：
Goode, Roland R.;Marshall, Susan J.;Chevli, K. Kent
背景 PCA3 尿液检测已显示出预测前列腺癌存在的前景。我们评估了该测试在接受初次和重复前列腺活检的患者中的价值。方法从 456 名前列腺活检前无前列腺癌个人史的男性中获取 PCA3 和 PSA 水平。 289 名男性接受了初次前列腺活检，167 名男性接受了重复前列腺活检。将PCA3和PSA水平与前列腺活检结果进行比较。结果显示PCA3评分与前列腺体积(P?=?0.162)和PSA水平(P?=?0.959)无关。与活检结果阴性的患者相比，前列腺活检的癌症患者的 PCA3 评分显着更高（P？
BACKGROUND The PCA3 urinary assay has shown promise in predicting the presence of prostate cancer. We evaluated the value of this test in patients undergoing initial and repeat prostate biopsy.METHODS PCA3 and PSA levels were obtained from 456 men with no known personal history of prostate cancer prior to prostate biopsy. Two hundred eighty-nine men underwent an initial prostate biopsy and 167 underwent a repeat prostate biopsy. PCA3 and PSA levels were compared to the prostate biopsy results.RESULTS PCA3 score was shown to be independent of prostate volume (P?=?0.162) and PSA level (P?=?0.959). PCA3 scores were significantly higher in patients with cancer on prostate biopsy compared to patients with negative biopsy results (P?